USPTO serial 86148901
ALIN
Reviewed by CopyMark Law Group
Reg. 4824753Status 710
- Filing date
- Status date
- Registration date
- Oct 6, 2015
- Examiner
- HUDSON, TAMARA BREE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ALIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Productos Farmaceuticos, S.A. de C.V.
Mexico, D.F., MX
Other trademarks owned by Productos Farmaceuticos, S.A. de C.V.
Productos Farmaceuticos, S.A. de C.V.
Mexico, D.F., MX
Other trademarks owned by Productos Farmaceuticos, S.A. de C.V.
Productos Farmaceuticos, S.A. de C.V.
Mexico, D.F., MX
Other trademarks owned by Productos Farmaceuticos, S.A. de C.V.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer A. Van Kirk
JENNIFER A. VAN KIRK LEWIS ROCA ROTHGERBER LLP19TH FL40 N CENTRAL AVEPHOENIX, AZ 85004Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, endocrinology for treatment of adrenal failure, thyroiditis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely rheumatology for treatment of rheumatoid arthritis, gout, post-traumatic arthritis, osteoarthritis, synovitis, bursitis, epicondylitis, ankylosing spondylitis, systemic or discoid lupus erythematosus, dermatomyositis, scleroderma, other collagen diseases, other osteoarticular diseases which require chronic corticosteroid administration; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory; immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely dermatology for treatment of pemphigus, erythema multiforme, exfoliative dermatitis, psoriasis, contact dermatitis, keloid lesions, hyperthrophic lichen planus, alopecia areata, urticaria, eczema, rosacea; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, allergology for treatment of bronchial asthma, urticaria, drug or food allergy, hypersensitivity reactions, allergic rhinitis, allergic sinusitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely otolaryngology for treatment of vasomotor rhinitis, other types of rhinitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, ophthalmology for treatment of allergic, acute or chronic conjunctivitis; scleritis, uveitis/iridocyclitis, optic neuritis, corneal infections, keratitis, marginal ulcers, throphic disorders, conjunctival/corneal physical/chemical burning, inflammatory reactions; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, gastroenterology for treatment of ulcerative colitis, regional enteritis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, pulmonology for treatment of bronchoaspiration, Löeffler syndrome, sarcoidosis, interstitial pulmonary fibrosis, chronic bronchitis, emphysema; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely hematology for treatment of autoimmune anemias or thrombocytopenias, leukemias, lymphomas, intravascular coagulation syndrome; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, oncology for treatment of nausea/vomiting associated with cancer chemotherapy prevention; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, miscellaneous for treatment of shock syndromes, cerebral edema | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Productos Farmaceuticos, S.A. de C.V.
- Other trademarks owned by Productos Farmaceuticos, S.A. de C.V.
- Other trademarks owned by Productos Farmaceuticos, S.A. de C.V.
- Other trademarks in Class 005
- Similar marks named ALIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 22, 2022 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Oct 6, 2020 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 6, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 21, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 1, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 15, 2015 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jun 15, 2015 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jun 3, 2015 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Jun 3, 2015 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jun 2, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 1, 2015 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 29, 2015 | APET | ASSIGNED TO PETITION STAFF | — |
| May 22, 2015 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 22, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 22, 2015 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Nov 25, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 30, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 30, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 10, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 22, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 21, 2014 | ALIE | ASSIGNED TO LIE | — |
| Aug 13, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 13, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 13, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 13, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 13, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 27, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 5, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 5, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 5, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 1, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 26, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 23, 2013 | NWAP | NEW APPLICATION ENTERED | — |